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Hemidesmus indicus (L.) R. Br. (HI) and Hibiscus rosa-sinensis L. (HRS) are widely used traditional medicine. We investigated
cardioprotective eﬀects of these plants applied for 15min at concentrations of 90, 180, and 360μg/mL in Langendorﬀ-perfused
rat hearts prior to 25-min global ischemia/120-min reperfusion (I/R). Functional recovery (left ventricular developed pressure—
LVDP, and rate of development of pressure), reperfusion arrhythmias, and infarct size (TTC staining) served as the endpoints. A
transient increase in LVDP (32%–75%) occurred at all concentrations of HI, while coronary ﬂow (CF) was signiﬁcantly increased
after HI 180 and 360. Only a moderate increase in LVDP (21% and 55%) and a tendency to increase CF was observed at HRS
180 and 360. HI and HRS at 180 and 360 signiﬁcantly improved postischemic recovery of LVDP. Both the drugs dose-dependently
reduced the numbers of ectopic beats and duration of ventricular tachycardia. The size of infarction was signiﬁcantly decreased
by HI 360, while HRS signiﬁcantly reduced the infarct size at all concentrations in a dose-dependent manner. Thus, it can be
concluded that HI might cause vasodilation, positive inotropic eﬀect, and cardioprotection, while HRS might cause these eﬀects
at higher concentrations. However, further study is needed to elucidate the exact mechanism of their actions.
1.Introduction
There is an increasing demand for the herbal drug treatment
for various ailments, and many plant drugs from traditional
medicine like Ayurveda are being explored globally.
Hemidesmus indicus (L.) R. Br. (Asclepiadaceae; HI)
is a twining shrub used as folk medicine and an ingre-
dient in Ayurvedic and Unani preparations. It is known
as Indian Sarsaparilla (English), Ananta, Gopasuta, Sariva
(Sanskrit), Anantamul (Hindi), Ushba Hindi (Urdu), Ush-
bahindi (Persian), and Irimusk (Sinhalese) [1]. The root
extract of HI was used for preparing herbal soft drinks
and as food during famine [2]. The plant has been used
traditionally for the treatment of blood disorders, low
digestion, anorexia, diarrhea, asthma, fever, cough, itching,
and skin diseases including leprosy [1]. Various eﬀects of HI,
such as hypoglycemic [3], hypolipidemic [4], antioxidant,
antithrombotic [5], antiinﬂammatory [6], antiulcerogenic
[7], hepatoprotective [8], renoprotective [9], and neutral-
ization of viper venom [10] have been reported. It mainly
comprises saponins, tannins, hemidesmine, hemidesmol,
hemidesterol, stearoptin, pregnane glycosides, β-sitosterol,
indicusin,coumarin,volatileoils,triterpines,ﬂavonoids,and
so forth [1, 7].
Hibiscus rosa-sinensis L. (Malvaceae; HRS) is an orna-
mental plant native to China, and found in India and
Philippines. It is called as Chinese rose, Shoe ﬂower
(English), Arkapriya, Japapushpa (Sanskrit), Jasund (Hindi),
Angharee-hind (Persian), and Wadamal (Sinhalese) [1]. In
some regions, the ﬂowers of HRS are eaten raw or cooked
[11] and made into a kind of pickle or used as a dye
for coloring foods, such as preserved fruits and cooked
vegetables [12, 13]. The young leaves are sometimes used
as a substitute for spinach [12, 13], while the roots are also
edible,butareﬁbrous,mucilaginous,andwithoutverymuch
ﬂavor [14]. In addition to its traditional value as emollient,2 Evidence-Based Complementary and Alternative Medicine
demulcent, emmenagogue, antiinﬂammatory, refrigerant,
aphrodisiac, anodyne, and laxative, various researchers had
described the use of the ﬂower to treat heart disorders
[1, 10, 15]. Sachdewa and Khemani [16] demonstrated
the antidiabetic activity of HRS in diabetic rats and the
eﬀect was comparable with glibenclamide. It has been also
shown to be beneﬁcial in fever and bronchial catarrh [16].
It is known to possess various activities like antidiarrheal,
antiphologistic, antispermatogenic, androgenic, antitumor
[16], antiestrogenic [17], antiimplantation [18, 19], wound
Healing [20], anticonvulsant [21], and so forth. It mainly
consists of ﬂavonoids, anthocyanins, quercetin, cyanidin,
kaempferol, hydrocitric acid, and so forth [1, 22].
However, till date, no research work has been performed
to study the eﬀects of HI and HRS in isolated heart
preparation. Hence, this study was initiated to evaluate the
potential myocardial protective eﬀect of both the drugs in
the model of ischemia-reperfusion (I/R) injury in rat hearts
in vitro.
2.MaterialsandMethods
2.1. Preparation of the Extract. Standardized dry extracts of
HI and HRS (prepared as below) were kindly gifted by Rumi
herbal researchinstitute, Chennai, India. In brief, dried roots
of HI were coarselypowdered and reﬂuxed with 50% ethanol
by hot percolation method and extracted. The yield was
23.18% of black-brown extractives containing 2.87mg% of
saponins and 1.62mg% tannins, heavy metals—arsenic—
not more than (NMT) 1 parts per million (ppm), lead NMT
1ppm, and E. coli and Salmonella were absent. Dried ﬂowers
of HRS were coarsely powdered and reﬂuxed with 80%
ethanol by hot percolation method and extracted. It yielded
15.6% of dark-brown extractives containing 4.16mg%
hydrocitric acid, heavy metals—arsenic—NMT 1ppm, lead
NMT 1ppm, and E. coli and Salmonella were absent.
The dry extract (600mg) was added to 15mL of boiling
distilled water and boiled for 2min. The decoction was
cooled and centrifuged to separate any undissolved material
and the supernatant was considered as a stock solution
containing 40mg/mL of the extract [23]. The decoction was
prepared fresh every day.
2.2. Animals. Male adult Wistar rats (230–270g) were used
in this study. Rats were housed under standard conditions
and supplied with drinking water and food ad libitum.A l l
procedures and experimental protocols were performed in
accordance with the G u i d ef o rt h eC a r ea n dU s eo fL a b o r a t o r y
Animals published by the US National Institutes of Health
and approved by the Animal Health and Animal Welfare
Division of the State veterinary and Food Administration of
the Slovak Republic.
2.3.PerfusionTechnique. Theratswereanesthetized(sodium
pentobarbitone, 60mg/kg, i.p.) and heparinized (500IU,
i.p.) [24]. Hearts were excised and rapidly mounted on
the Langendorﬀ perfusion apparatus. Retrograde perfusion
in a nonrecirculating mode was established at a constant
perfusion pressure of 70mmHg and 37◦C. Krebs-Henseleit
buﬀer (KHB) gassed with 95% O2 and 5% CO2 (pH 7.4)
containing (mM) NaCl 118.0, KCl 4.7,MgSO4·7H2O 1.18,
NaHCO3 25.0, KH2PO4 1.18, CaCl2·2H2O 2.25, and glucose
11.1 was used as the perfusion medium. The perfusate was
ﬁltered through a 5-μm porosity ﬁlter (Millipore), before it
entered the heart. An epicardial electrogram was registered
using two stainless steel electrodes, one attached to the apex
of the heart and the other to the aortic cannula.
Left ventricular (LV) pressure was measured using a
nonelastic water-ﬁlled balloon inserted into the left ventricle
via the left atrium (adjusted to obtain end-diastolic pressure
of 4–7mmHg) and connected to a pressure transducer
(MLP844 Physiological Pressure Transducer, ADInstru-
ments). Left ventricular developed pressure (LVDP, systolic
minus diastolic pressure), maximal rate of pressure develop-
ment (+dP/dtmax) as an index of contraction, heart rate (HR;
derived from electrogram), and coronary ﬂow (CF) were
monitored continuously. The hearts were allowed to stabilize
(15min) before further interventions. Baseline values of
functional parameters were recorded after stabilization and
recording of the data was performed until the end of
an experiment, except for the contractile function, as the
balloon was deﬂated after 40min of R. Heart function and
arrhythmias were analyzed using PowerLab/8SP Chart 5
software (ADInstruments).
Recovery of function was expressed as a percentage of
preischemic baseline values.
2.4. Experimental Protocol. The experimental protocol con-
sistedofastabilizationperiod(15min),perfusionwithdrugs
dispersed in KHB at the required concentrations for 15min,
global ischemia (25min), and reperfusion period (120min).
All animals were randomly divided to the following
groups (seven rats per group).
(1) Control (C): hearts were perfused with KHB
throughout the experiment.
(2) HI 90: hearts were perfused with HI extract at a
concentration of 90μg/mL in KHB for 15min, prior
to ischemia and reperfusion with KHB.
(3) HI 180: hearts were perfused with HI extract at a
concentration of 180μg/mL in KHB for 15min, prior
to ischemia and reperfusion with KHB.
(4) HI 360: hearts were perfused with HI extract at a
concentration of 360μg/mL in KHB for 15min, prior
to ischemia and reperfusion with KHB.
(5) HRS 90: hearts were perfused with HRS extract at a
concentration of 90μg/mL in KHB for 15min, prior
to ischemia and reperfusion with KHB.
(6) HRS 180: hearts were perfused with HRS extract at a
concentration of 180μg/mL in KHB for 15min, prior
to ischemia and reperfusion with KHB.
(7) HRS 360: hearts were perfused with HRS extract at a
concentration of 360μg/mL in KHB for 15min, prior
to ischemia and reperfusion with KHB.Evidence-Based Complementary and Alternative Medicine 3
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Figure 1: Eﬀect of HI (a) and HRS (b) on the time course of LVDP recovery after I/R expressed as a percentage of the baseline values.
∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001 versus C. n = 7.
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Figure 2: Eﬀect of HI (a) and HRS (b) on +dP/dtmax at 40min of R. ∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001, n = 7.
2.5. Quantiﬁcation of Arrhythmias. Susceptibility to ventric-
ular arrhythmias was analyzed from the electrogram record-
ing during the ﬁrst 10min of R, as per the guidelines for
thestudyofischemia-andreperfusion-inducedarrhythmias,
known as the Lambeth conventions [25]. We focused on the
measurement of the total number of ventricular premature
beats (VPB), as well as on the total duration of the episodes
of ventricular tachycardia (VT), which was deﬁned as a run
of four or more consecutive ectopic beats.
2.6. Infarct Size Determination. The measurement of infarct
size using triphenyl tetrazolium staining was essentially
identical to that described by Ravingerov´ a et al. [26]. In
brief, at the end of R, the hearts were stained with 1%
2,3,5-triphenyl tetrazolium chloride (Sigma, USA) dissolved
in 0.1M phosphate buﬀer (pH 7.4). The hearts were then
stored overnight in 10% neutral formaldehyde solution and
cut perpendicularly to the long axis of the ventricle into 1-
mm thick slices. The infarct area (IA) and the area at risk
(AR), which in the setting of global ischemia was the whole
mass of the left ventricle, were measured by a computerized
planimetric method. The infarct size was normalized to the
size of the area at risk (IA/AR).
2.7. Statistical Evaluation. T h ed a t aw e r ee x p r e s s e da sm e a n
±S.E.M.Thestatisticalanalysiswasperformedwithone-way
ANOVA followed by Newman-Keuls multiple comparison
test or two-way ANOVA followed by Bonferroni post tests.
Diﬀerences were considered signiﬁcant when P ≤ .05.4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀe c to fH Io nL V E D Pa t4 0m i no fR .∗P<. 05, ∗∗∗P<
.001, n = 7.
3. Results
3.1. Preischemia. After 15-min stabilization of all the hearts
with KHB, the perfusion was switched to the drug-
containing KHB solution. During perfusion with HI, we
observed a transient increase in LVDP that occurred during
perfusion with HI 90 (32%), HI 180 (52%), and HI 360
(75%) when compared with predrug values. Table 1 shows
that at the end of 15min perfusion with HI, LVDP and HR
were similar to those of pre-drug values at all doses, while
CF was signiﬁcantly increased by HI 180 (P<. 05) and HI
360 (P<. 01) when compared with pre-drug values (8.8 ±
0.3mL/min).
When the hearts were perfused with HRS, a transient
increase in LVDP at HRS 180 (21%) and HRS 360 (55%) was
observed when compared with pre-drug values. At the end
of 15-min perfusion with HRS, there was only a tendency to
increase CF, and no signiﬁcant changes in LVDP and HR at
all doses (Table 1).
3.2. Post-Ischemic Recovery of Function
3.2.1. LVDP. Figure 1(a) shows the time course of post-
ischemic recovery of LVDP. At 40min of R, HI 180 and HI
360 signiﬁcantly (P<. 05 and P<. 001, resp.) improved
the recovery of LVDP to 52.7 and 81.2%, respectively, when
compared with 19.4% in the nontreated C group. The
changes in the LVDP recovery induced by HI 90 were not
signiﬁcant at any time point.
Figure 1(b) depicts the time course of post-ischemic
LVDP recovery in the presence of HRS. HRS 90 did not exert
anyeﬀectwhenc ompar edwithC.H o wev er ,HRS180ex erted
am o r ep r o n o u n c e de ﬀect on recovery of LVDP and was
signiﬁcant at few time points. HRS 360 showed a signiﬁcant
recovery at all time points after 20min of R. At the end of
40min of I/R, both HRS 180 and HRS 360 induced almost
similar recovery which was signiﬁcantly (P<. 01) better
when compared with C.
3.2.2. +dP/dt. Figure 2(a) shows the recovery of +dP/dtmax
at 40min of I/R. When compared with C, the recovery was
signiﬁcant when the hearts were perfused with HI 90 (P<
.05), HI 180 (P<. 001), and HI 360 (P<. 001). The recovery
of +dP/dtmax was dose-dependent, that is, HI 360 induced a
signiﬁcantly higher recovery (P<. 001) than HI 90 and HI
180.
The recovery of +dP/dtmax was signiﬁcantly (P<. 01)
betterwhencomparedwithC,whentheheartswereperfused
with HRS 180 and HRS 360. HRS 180 and HRS 360 showed
a signiﬁcantly stronger eﬀect (P<. 01) than HRS 90
(Figure 2(b)).
3.2.3. LVEDP. Figure 3 shows the recovery of LVEDP, which
was signiﬁcantly lowered by all concentrations of HI, HI 90
(P<. 05), HI 180 (P<. 001), and HI 360 (P<. 001).
Furthermore, perfusion with HI 360 led to a signiﬁcantly
better recovery of LVEDP when compared with HI 90 and
HI 180 (P<. 001 and P<. 05, resp.).
HRS did not cause an improvement of LVEDP recovery
(in mmHg) at any concentration HI 90 (77.8 ± 3.5), HI 180
(68.2 ± 1.8), HI 360 (67.3 ± 2.4), in comparison to C (78.6
± 4.7).
3.2.4. Arrhythmias. HI exerted a signiﬁcant antiarrhythmic
protection at HI 90, HI 180, and HI 360 manifested by a
reduced number of PVB (P<. 05, P<. 001, and P<. 001,
resp.).Theprotectionwasalsodosedependent(Figure 4(a)),
as perfusion with HI 360 resulted in a signiﬁcantly lower
number of PVB than HI 90 (P<. 001) and HI 180 (P<
.05), while HI 180 induced a signiﬁcantly (P<. 001) lower
number of PVB than HI 90. There was also a signiﬁcantly
(P<. 01) shorter duration of episodes of VT at HI 180 (9.8
± 3.0s) and HI 360 (5.3 ± 2.8s), but not at HI 90 (28.5 ±
9.7s), when compared with 39 ± 6.5 s in C.
Interestingly, HRS 90, HRS 180, and HRS 360 signiﬁ-
cantly (P<. 001) reduced the number of PVB and decreased
the duration of VT (P<. 05) to 19.8 ± 6.8, 13.7 ± 5.6, and
13.2 ± 5.1s, respectively, when compared with nontreated C
(Figure 4(b)).
3.2.5. Infarct Size. The size of infarction (percentage of
the risk area; IA/AR) was signiﬁcantly reduced only after
administration of HI 360 (20.3 ± 1.4%; P<. 01) and not
at HI 90 (33.5 ± 5.3%) and HI 180 (30.1 ± 4.9%), when
compared with C (43.2 ± 2.4%).
Theinfarctsizewassigniﬁcantly(P<. 01)smalleratHRS
90(29.4±4.7%),HRS180(24.8±3.6%),andHRS360(22.5
± 2.4%), when compared with C.
4. Discussion
The extracts of HI and HRS were tested for their potential
protective eﬀect on I/R-induced lethal injury and functional
deterioration. The eﬀects of the extracts were evaluated
before I and during R. The widely used model of 25-min
global I for optimum functional deterioration [27], followed
by 120min of R for suﬃcient development of necrosis and
infarct size determination in the Langendorﬀ setup [28–30]
was utilized.Evidence-Based Complementary and Alternative Medicine 5
Table 1:Eﬀectof15-minperfusionwithHIandHRSonhemodynamicparametersoftheisolatedratheart.LVDP:leftventriculardeveloped
pressure (LV systolic minus diastolic pressure); HR: heart rate; CF: coronary ﬂow; BD: Before Drug (pre-drug values). ∗P<. 05, ∗∗P<. 01
versus BD (baseline).
BD
HI
BD
HRS
pre-ischemia pre-ischemia
HI 90 HI 180 HI 360 HRS 90 HRS 180 HRS 360
LVDP (mmHg) 89.5 ± 9.1 83.9 ± 2.2 84.8 ± 1.9 82.2 ± 7.5 83.9 ± 4.0 77.6 ± 3.5 82.6 ± 3.2 80.7 ± 2.8
HR (BPM) 302.6 ± 22.6 290.1 ± 31.5 286.6 ± 9.7 299.4 ± 33.1 305.8 ± 11.4 284.1 ± 9.3 290.0 ± 23.8 292.1 ± 13.8
CF (mL/min) 8.8 ± 0.3 14.1 ± 2.8 17.7 ± 2.5∗ 20.6 ± 2.7∗∗ 8.8 ± 0.4 10.5 ± 0.9 11.0 ± 2.2 12.4 ± 1.6
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Figure 4: Eﬀect of HI (a) and HRS (b) on arrhythmias (PVB) during the ﬁrst 10min of R. ∗P<. 05, ∗∗∗P<. 001, n = 7.
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Figure 5: Potential mechanisms for the beneﬁcial eﬀects of HI and
HRS in I/R rat hearts.
HI had a dose-dependent eﬀect on the recovery of LVDP
and +dP/dtmax. HRS had a similar eﬀect on the recovery
of LVDP and +dP/dtmax at HI 180 as in HRS 360 and no
protection was observed at HRS 90, suggesting that HRS
180 is the minimum dose required to increase the recovery
of contractile function. The signiﬁcantly better recovery of
LVEDP and attenuation of post-ischemic diastolic dysfunc-
tion at all three doses of HI infers that HI could improve
myocardial relaxation and may reduce the edema caused by
I/R injury [31]. In contrast, HRS did not have any signiﬁcant
activity towards the relaxation of the cardiac muscle at any
dose.
HI could protect the heart from arrhythmias at all doses
in a dose-dependent manner manifested by a reduced num-
ber of PVB (extra heart beat caused by abnormal electrical
activity). In addition, a signiﬁcantly lower total duration
of episodes of VT (rapid heart rhythm) was observed at
higher doses. Interestingly, HRS at all doses had a signiﬁcant
protection against arrhythmias. The size of infarction (death
of a macroscopic area of cardiac tissue) was signiﬁcantly
reduced by HI at the highest dose, while HRS signiﬁcantly
lowered the infarct size at all the doses. In comparison, after
25-min I, HI exerted a higher protective activity against
functional deterioration and a moderate protection against
arrhythmias and infarct size, while HRS had a moderate
eﬀect on functional recovery and a stronger protection in
terms of antiarrhythmic eﬀect and infarct size limitation.
In two diﬀerent studies recently performed in our
laboratory in a similar model, N-acetylcysteine (4mM)
[27]a n dq u e r c e t i n( 1 5μM) [32] were found to protect the
myocardium against I/R. In the present study, the recovery
of various parameters in the presence of both the extracts
was comparable with that of N-acetylcysteine (LVDP—50%)6 Evidence-Based Complementary and Alternative Medicine
and quercetin (LVDP—39.4%, +dP/dtmax—30.9%, IA/AR—
14.3%). At higher concentrations, the extracts showed a
bettereﬀectthanquercetin[27,32].Functionaldeterioration
and severe arrhythmias upon reperfusion were found to be
related, to a certain extent, to an excessive generation of
reactive oxygen species (ROS) during prolonged I/R [33–
36]. ROS may also participate in I/R injury through the
depression of sarcoplasmic reticulum (SR) Ca2+ handling by
modulating gene expression in the I/R heart [37]. This has
been veriﬁed by the eﬃcacy of antioxidants and scavengers
in the experimental settings of acute I/R [38–41]. Similarly,
pre-treatment with antioxidants, such as melatonin [38, 39]
and N-acetylcysteine [27] prior to I reduced the severity and
duration of R-induced ventricular arrhythmias in isolated
perfused rat hearts, attenuated calcium overload of the
heart [40, 42], and improved post-ischemic recovery of the
contractile function [38].
The previously reported antioxidant eﬀect of HI [5, 43]
may be associated with tannins, one of the main constituents
[44]. Likewise, saponins have also been shown to have
beneﬁcial eﬀects on cardiovascular diseases [45]. Flavonoids
produce vasodilation by regulating endothelial nitric oxide
(NO) production [46] and interaction with ion channels
[47]. Moreover, ﬂavonoids are known to protect the I/R-
induced myocardial injury by their multifaceted properties,
such as antioxidant, antiinﬂammatory, vasodilatory, and
antiplatelet aggregation [47]. Therefore, it is conceivable
that the cardioprotective eﬀect of HI may be related to the
combined eﬀects of saponins, tannins, and ﬂavonoids. HRS
has been shown to enhance the endogenous antioxidant
activity and protect the heart from isoproterenol-induced
injury [48]. Quercetin has been shown to reduce blood
pressureandexhibitendothelium-dependentvasodilationby
enhancing eNOS activity [46, 49–51]. In addition, cyanidin
and quercetin are known to possess antioxidant activity
[48, 49]. Kim et al. [52] have shown that kaempferol pro-
tected the cardiac muscle cells against I/R-induced damage
by increasing the expression of antiapoptotic protein and
downregulating the expression of endoplasmic reticulum
stress proteins. Thus, the combined eﬀect of constituents of
HRS, such as quercetin, cyanidin, and kaempferol might be
responsible for the beneﬁcial eﬀects (Figure 5).
In conclusion, HI might cause vasodilation, positive
inotropic eﬀect, and cardioprotection, while HRS might
cause these eﬀects at higher concentrations. In addition,
based on the drug eﬀects observed at lower doses, it could
be suggested that the suppression of arrhythmias results in a
smallersizeofinfarctionthanthatachievedbytheprotection
against contractile dysfunction. However, further study is
required to explore the in vivo activity of both the plants.
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